Periodic Reporting for period 1 - CellFoam (A novel tissue remodelling biomaterial to offer a revolutionary solution for treating Urinary Incontinence in dogs)
Reporting period: 2017-03-01 to 2017-08-31
We have created a new material: CellFoam™ is a novel biomaterial offering a true revolution in the field of tissue engineering due to its capacity as a scaffold and tissue adhesive.
CellFoam™ can solve in one short endoscopic procedure the unmet needs of urinary incontinence. It will provide long-term efficacy, quality of life reassurance for dogs and also for their owners.
Our objective is to accelerate the market adoption and international penetration of CellFoam™, focusing ourselves on reducing the risks (commercial, technical and financial) and preparing for the commercialization at the international level (including route-to-market, marketing strategy, growth strategy, etc.). Thus, we pursue to minimize the risks and maximize the chances of success while creating a business that is financially sustainable and can have positive cash flow in the long run.
The company has finished running the clinical trial in Israel (15 dogs) and will commence a follow up for 1 year after which the company will publish the results in a peer reviewed setting.
During the clinical trials, the company identified technical weak points in the product. Those weak points were corrected by an R&D effort enabling the urologist better control of material delivery and increased working time.
Improving the product from a technical viewpoint and enhancing it with new features and functionalities will allow us to have a market ready product (2nd generation) by mid-2018, but pending additional funding.